NeuroOne CBO buys 33,333 shares at about $2

NeuroOne Medical Technologies’ chief business officer bought shares and received a new stock option grant, increasing his direct equity exposure to NMTC.

Rhea-AI Filing Summary

NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) Chief Business Officer David J. Wambeke reported two insider transactions. On August 27, 2026, he purchased 33,333 shares of common stock at a weighted average price of about $2.01 per share, with individual trade prices between $2.00 and $2.017, bringing his direct common share holdings to 199,999 shares. On August 28, 2026, he received a grant of 35,000 stock options with an exercise price of $1.77 per share, expiring on August 27, 2036; 25% of these options will vest on August 28, 2027 and the remaining 75% will vest in 12 equal quarterly installments. No Rule 10b5-1 trading plan is reported for these transactions.

Insider Trade Summary

Net Buyer: 33,333 shares

Net Buy 2 txns

Insider Wambeke David J.

Role Chief Business Officer

Bought 33,333 shs ($67K)

Type	Security	Shares	Price	Value
Grant/Award	Option to Purchase Common Stock F2	35,000	$0.00	$0.00
Purchase	Common Stock F1	33,333	$2.01	$67K

Holdings After Transaction: Option to Purchase Common Stock — 35,000 contracts (Direct); Common Stock — 199,999 shares (Direct)

Footnotes (2)

1. F1. The price represents the weighted average price of the multiple transactions reported on this line. The shares were sold at prices ranging from $2.00 and $2.017 per share. Upon request by the SEC staff, the issuer or any securityholder of the issuer, the reporting person will provide full information regarding the number of shares sold at each separate price.
2. F2. 25% will vest on August 28, 2027, and the remaining 75% will vest in 12 equal quarterly installments.

Key Figures

Common shares purchased: 33,333 shares Weighted average purchase price: About $2.01 per share Direct common shares after purchase: 199,999 shares +5 more

8 metrics

Common shares purchased 33,333 shares Open-market purchase on August 27, 2026

Weighted average purchase price About $2.01 per share Common stock purchase on August 27, 2026; individual prices from $2.00 to $2.017

Direct common shares after purchase 199,999 shares Direct holdings following the August 27, 2026 purchase

Stock options granted 35,000 options Grant on August 28, 2026 to acquire common stock

Option exercise price $1.77 per share Exercise price for 35,000 options granted August 28, 2026

Option expiration date August 27, 2036 Expiration of 35,000 stock options

Initial vesting portion 25% Portion of options vesting on August 28, 2027

Remaining vesting installments 12 quarterly installments Schedule for vesting of remaining 75% of options

Key Terms

weighted average price, vest, quarterly installments

3 terms

weighted average price financial

"The price represents the weighted average price of the multiple transactions"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

vest financial

"25% will vest on August 28, 2027, and the remaining 75% will vest"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

quarterly installments financial

"the remaining 75% will vest in 12 equal quarterly installments"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider share purchase did NMTC disclose for David J. Wambeke?

David J. Wambeke purchased 33,333 shares of NeuroOne Medical Technologies common stock on August 27, 2026 at a weighted average price of about $2.01 per share, with individual trades executed between $2.00 and $2.017 per share.

How many NMTC shares does David J. Wambeke hold after the reported transactions?

After the reported purchase on August 27, 2026, David J. Wambeke directly holds 199,999 shares of NeuroOne Medical Technologies common stock. This figure reflects his direct ownership immediately following that transaction.

What stock option grant did NMTC report for David J. Wambeke?

On August 28, 2026, David J. Wambeke received a grant of 35,000 stock options to acquire NeuroOne Medical Technologies common stock at an exercise price of $1.77 per share, with an expiration date of August 27, 2036.

What is the vesting schedule of David J. Wambeke’s new NMTC stock options?

For the 35,000 stock options granted on August 28, 2026, 25% will vest on August 28, 2027. The remaining 75% will vest in 12 equal quarterly installments thereafter, according to the disclosed vesting terms.

Were David J. Wambeke’s NMTC transactions made under a Rule 10b5-1 trading plan?

No. The filing indicates that no Rule 10b5-1 trading plan is reported in connection with these transactions by David J. Wambeke in NeuroOne Medical Technologies stock and options.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/08/2026 - 08:32 AM EDT Accepted by SEC EDGAR 09/08/2026 - 08:31 AM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wambeke David J.

(Last) (First) (Middle)

C/O NEUROONE MEDICAL TECHNOLOGIES CORP

7599 ANAGRAM DRIVE

(Street)

EDEN PRAIRIE MINNESOTA 55344

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NEUROONE MEDICAL TECHNOLOGIES Corp [ NMTC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/27/2026		P		33,333	A	$2.01(1)	199,999	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Purchase Common Stock	$1.77	08/28/2026		A		35,000		(2)	08/27/2036	Common Stock	35,000	$0	35,000	D

Explanation of Responses:

1. The price represents the weighted average price of the multiple transactions reported on this line. The shares were sold at prices ranging from $2.00 and $2.017 per share. Upon request by the SEC staff, the issuer or any securityholder of the issuer, the reporting person will provide full information regarding the number of shares sold at each separate price.

2. 25% will vest on August 28, 2027, and the remaining 75% will vest in 12 equal quarterly installments.

	/s/ Emily Johns, by Power of Attorney	09/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)